Phase II Study of Temozolomide and Thalidomide in Patients with Unresectable or Metastatic Leiomyosarcoma

Table 2

Response, location of primary disease, prior therapy, and duration of therapy (days).

Enrolled patient ID No.	Response	Primary site of disease	Prior chemotherapy regimens	Duration of therapy (days)
1	PD	Colon and duodenum	Dox	34
2	PD	Uterus	Dox/taxotere; Ifos/DTIC/etoposide; gleevec	16
3	PD	Uterus	Dox/ifex; gem/taxotere	37
4	PD	Stomach	Gleevec; ifex/dox	8
5	PD	Retroperitoneal	Doxil; ifos; taxotere/gem; digitoxin	25
6	SD	Unknown	Dox/ifex	^*114/398
7	PD	Iliopsoas	Dox; gem/taxotere	42
8	PR	Retroperitoneal	None	^*382/389
9	PD	Ovarian	Doxo/ifex; gem/taxotere	45
10	PD	Uterus	Doxil, gem	62
11	PD	Uterus	Gem/taxotere	56
12	PD	Pelvic mass	Gem/taxotere	^*36/62
13	PR	Uterus	Dox/ifos; gem/taxotere	670
14	PD	Unknown	DTIC/doxo; gem/taxotere; digitoxin; ifos	50
15	SD	Uterus	Dox/ifox/taxotere	186
16	PD	Uterus	Gem/taxotere	52
17	SD	Uterus	Dox; gem; taxotere	143
18	SD	Uterus	None	^*157/207
19	PD	Colon	None	37
20	PD	Uterus	Ifos; gem	^*30/53
21	PD	Kidney	None	78
22	PD	Small bowel	Dox/avastin; gem; DTIC	53
23	SD	Retroperitoneal	MAID; vin/doxo/cytoxan	383
24	PD	Uterus	Gem/taxotere	36

^*For the 5 patients who discontinued thalidomide early, the fraction represents duration of therapy in days for Temodar + Thalidomide over total days of therapy with Temodar.